Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia. - Wikidata - awgldk - TriplyDB

Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

http://www.wikidata.org/entity/Q38008650

about

Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.Revealing the Effects of the Herbal Pair of Euphorbia kansui and Glycyrrhiza on Hepatocellular Carcinoma Ascites with Integrating Network Target Analysis and Experimental Validation Effect of Glycyrrhiza on the Diuretic Function of Euphorbia kansui: An Ascites Mouse Model Implications of Hyponatremia in Liver Transplantation Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial.Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy.

P2860

Q26778032-3FDD666F-BD7A-42F6-9D95-5C84009867CD Q34093932-D32EF400-F722-4F48-9F15-BB1D558C28CD Q35657152-B4E40DA0-3DE0-46A1-BDAB-0DB47B6F7D19 Q36855036-1D9A034A-C9F8-4320-8D82-B7E46A646975 Q36924811-81AABACD-C76E-4135-B510-AE7C4B8D0345 Q42087113-1E3DDE7A-04D3-458F-A160-56F7A415428C Q45107672-EA123E17-37F7-4C69-9175-CCEA57DC4933 Q51211871-B81631F3-ADFA-4E4B-9CE8-6A9B718CFA45

P2860

Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

http://www.wikidata.org/entity/Q38008650

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

@en

type

label

Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

@en

prefLabel

Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

@en

P1433

Q38008650-456C44EC-66AF-4194-872B-9CD97C4A09E8

P1476

Q38008650-10F15AEC-E6DC-43EC-899B-B15C2819E4C8

P2093

Q38008650-691AB0EE-B33B-4779-9B8E-B805021BD3F0

Q38008650-80DDBBB7-D435-4D06-9990-DC2F592FB229

P2860

Q38008650-1D84F5B6-5CEA-48A9-BE11-EA1858A2CBC9

Q38008650-2B78FB4D-1AB9-46CF-B9FD-528EDACE9258

Q38008650-2CA1A4BE-AD45-48D2-A67B-0BEAD2C550B5

Q38008650-403E4E91-2D66-4028-AA37-6F2CB0C35B88

Q38008650-56E14EB7-D375-461E-8C3E-DE9E752A7608

Q38008650-58BC543D-AA9B-4B75-8C45-BBE6D45746AC

Q38008650-61C17150-5DDF-42A4-AEBF-AFC6F4A53578

Q38008650-69ECEDE8-91D0-45D0-9C50-D29C08F13FCC

Q38008650-7924F06A-6453-4BEA-BA99-F14B87D289EA

Q38008650-8A526918-6CC7-4972-B76F-0ED1D3FCC201

P304

Q38008650-50350A0C-EB2C-46B7-9EB2-302D074043F1

P31

Q38008650-2700A2AE-A6ED-46E2-A73D-6F6C0B84676F

P356

Q38008650-5A31AA47-BC1F-4785-A84C-D72C220E2D8A

P433

Q38008650-6E26465C-2F62-43FF-A29F-98500165F521

P478

Q38008650-F7D258B9-5F74-481D-898B-5A2B617AAA5C

P577

Q38008650-0E534335-0F7C-4FB5-A889-850315645328

P698

Q38008650-F9D19A25-3A56-4B7A-B853-DE85FA8E0906

P921

Q38008650-91a14967-9ce0-4638-a02e-f96d91989bb2

P932

Q38008650-911FA3BE-670A-4877-9E01-69072729B367

P356

1756283X12437357

P1433

Therapeutic Advances in Gastroenterology

P1476

Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

@en

P2093

Shahid Habib

http://www.w3.org/2001/XMLSchema#string

Thomas D Boyer

http://www.w3.org/2001/XMLSchema#string

P2860

Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.

Oral tolvaptan is safe and effective in chronic hyponatremia

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

Vasopressin antagonists.

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.

Hyponatremia and mortality among patients on the liver-transplant waiting list

The management of ascites and hyponatremia in cirrhosis.

Vasopressin antagonists in the treatment of water-retaining disorders.

Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis.

P304

189-197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X12437357

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22570679

http://www.w3.org/2001/XMLSchema#string

P921

P932

3342571

http://www.w3.org/2001/XMLSchema#string